All-or-Nothing Bet on New Bristol Myers Drugs Faces First Test

(Bloomberg) -- An upcoming U.S. regulatory decision for Bristol Myers Squibb Co.’s multiple sclerosis treatment marks the first of three key milestones that will dictate the fate of its all-or-noth...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.